US2498453065 - Common Stock
DERMATA THERAPEUTICS INC
NASDAQ:DRMA (4/25/2024, 3:08:43 PM)
0.3401
-0.02 (-4.68%)
Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. The company is headquartered in San Diego, California and currently employs 8 full-time employees. The company went IPO on 2021-08-13. The firm is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its product candidates include DMT310 and DMT410. Its lead product candidate DMT310 is intended to utilize its Spongilla technology for the once-weekly treatment of a variety of skin diseases with its initial focus being on the treatment of acne vulgaris. DMT310 completed a Phase Ib proof of concept (POC) trial in psoriasis. Its second product candidate utilizing its Spongilla technology is its combination treatment, DMT410. DMT410 is intended to consist of one treatment of its sponge powder followed by one topical application of botulinum toxin for delivery into the dermis. DMT410 Phase I POC trial of DMT410 for the treatment of multiple aesthetic skin conditions, including reduction of pore size, sebum production, and fine lines.
DERMATA THERAPEUTICS INC
3525 Del Mar Heights Rd., #322
San Diego CALIFORNIA
P: 18582230882
CEO: Gerald T. Proehl
Employees: 8
Website: https://www.dermatarx.com/
It's time to start ofd the trading week with a look at the biggest pre-market stock movers traders need to watch on Monday morning!
Dermata Therapeutics just reported results for the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Dermata Therapeutics (NASDAQ:DRMA) just reported results for the fourth quarter...
Applied Therapeutics stock is tumbling on Friday as investors react to lackluster results from a Phase 3 clinical trial of AT-001.
Dermata Therapeutics (DRMA) stock soared 62% in pre-market trading Friday after the company announced it had been granted a patent in Japan for its DMT410 hyper
CISO Global stock is falling on Friday as investors in the company react to a new delisting notice over the low trading price of the shares.
Here you can normally see the latest stock twits on DRMA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: